Kisspeptin-10
What Is Kisspeptin-10? The Decapeptide, Its Receptor and the Human Studies
EC
· 9 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 7 sections
Kisspeptin-10 is a ten-residue peptide, Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, cut from the C-terminal end of the protein encoded by the KISS1 gene. It is the shortest form with full activity at the kisspeptin receptor, KISS1R (once called GPR54), which sits above gonadotropin-releasing hormone (GnRH) in the hormone chain that controls the testes and ovaries. In healthy men it raises LH within half an hour. It is a research tool, approved nowhere as a medicine.

Where does kisspeptin-10 come from?
From a gene first studied for a completely different reason. In 1996 Lee and colleagues isolated a new gene, KiSS-1, from melanoma cells whose ability to spread had been suppressed; it was expressed in non-metastatic melanoma cells but not metastatic ones, most strongly in placenta, and transfecting it suppressed metastasis (PMID 8944003). The name stuck to the gene long before anyone knew what it did in normal physiology.
In 2001 two groups found its products. Takeda's Ohtaki and colleagues isolated a 54-residue amidated peptide from human placenta as the natural ligand of an orphan receptor and named it metastin (PMID 11385580). Kotani and colleagues in Brussels isolated 54-, 14- and 13-residue peptides sharing an RF-amide C-terminus, named them kisspeptins, and showed they activated GPR54, a receptor highly expressed in placenta, pituitary, pancreas and spinal cord (PMID 11457843). Kisspeptin-10 is the last ten residues common to all of them.
The reproductive role arrived in 2003. Two groups found that people with loss-of-function mutations in GPR54 had isolated hypogonadotropic hypogonadism: they did not go through puberty because the signal for GnRH release was missing (PMID 12944565; PMID 14573733). That discovery turned a metastasis gene into the gatekeeper of the reproductive axis, and is the reason human studies of kisspeptin exist at all. The three-level hormone chain it sits above is explained in the HPG axis and kisspeptin.
| Property | Kisspeptin-10 |
|---|---|
| Sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (YNWNSFGLRF-NH2) |
| Origin | C-terminal decapeptide of the KISS1 gene product, shared by kisspeptin-54, -14 and -13 |
| CAS number (PubChem) | 374675-21-5 |
| Molecular formula (PubChem) | C63H83N17O14 |
| Molecular weight (PubChem) | About 1,302 g/mol |
| Receptor | KISS1R (GPR54) |
| Evidence stage | Human physiology studies in healthy volunteers; no therapeutic trial of kisspeptin-10 |
| Regulatory status | Approved nowhere; no Health Canada authorisation found |
How does kisspeptin-10 work?
Kisspeptin acts on GnRH neurons in the hypothalamus. Activating KISS1R makes those neurons release GnRH, which in turn makes the pituitary release luteinising hormone (LH) and follicle-stimulating hormone (FSH), and those drive testosterone or oestradiol production in the gonads. Kisspeptin-10 therefore acts two steps above the sex steroids and one step above GnRH.
That position is what makes it useful as a research tool. A GnRH test asks whether the pituitary can respond. A kisspeptin test asks whether the hypothalamic GnRH neurons can respond, which is a different question and one that has been hard to put to people any other way.
What has kisspeptin-10 been studied for in humans?
Almost entirely as a probe of normal physiology, in small studies from a few academic groups, mainly in Edinburgh and London. The detailed reading of that literature is in kisspeptin-10: what the human neuroendocrine literature measured. The main findings:
It works in men. George and colleagues, who describe kisspeptin-10 as the minimal sequence with full intrinsic bioactivity, reported a rapid rise in LH in healthy men in step with the amount given, up to a point: the highest level tested produced a smaller response than the one below it (PMID 21632807). Sustained exposure raised LH, testosterone, and the frequency and size of LH pulses, with testosterone rising from 16.6 to 24.0 nmol/L in the group studied.
Women respond only at some points in the cycle. Jayasena and colleagues gave kisspeptin-10 to healthy men and women (PMID 21976724). Men responded at low levels. Women in the early, follicular phase of the menstrual cycle showed no gonadotropin change at the highest levels tested, while women in the preovulatory phase did respond. The authors called this sexual dimorphism, and it is one of the more important facts about the molecule: a result in men does not predict a result in women.
It is less potent than GnRH and similar to kisspeptin-54 in men. In a direct comparison, LH and FSH were about three times higher with GnRH than with kisspeptin-10, and the two kisspeptin forms produced similar gonadotropin levels (PMID 26089302). The study had five men per group.
Continuous exposure fades; intermittent exposure held up in one study. A 2026 study in healthy men from Imperial College found that kisspeptin-10 raised LH, FSH and testosterone acutely, but under continuous exposure for five days gonadotropins returned to the levels seen with vehicle while testosterone stayed raised. Intermittent exposure sustained gonadotropin rises over 12 days, and the receptor still responded at the end (PMID 42549827). Fifteen men took part.
The length difference between kisspeptin-10 and the long form, and why the IVF oocyte-maturation trials used kisspeptin-54 rather than kisspeptin-10, is covered in kisspeptin-10 vs kisspeptin-54.
What does the evidence not show?
The human studies measure hormones in blood. They do not test any clinical outcome, they are small, and almost all of them are single-site physiology studies rather than randomised therapeutic trials. Testosterone rising for a few days in small groups of healthy men is a fact about the axis, not evidence of a benefit for anyone. Why small mechanistic studies cannot be read as efficacy results is covered in how to read a peptide study.
The translational work that does aim at treatment has largely moved away from kisspeptin-10. The IVF trials used kisspeptin-54, and drug development has turned to engineered receptor agonists such as MVT-602, which in randomised trials in healthy women produced an LH rise of similar amplitude and duration to the natural mid-cycle surge (PMID 37925096). Neither is approved.
Is kisspeptin-10 approved anywhere?
No. We found no approval for kisspeptin-10, or any kisspeptin, from Health Canada, the FDA or the EMA. It does not appear among the examples in Health Canada's April 2026 advisory on unauthorized peptides, but that advisory states that many other unauthorized peptides exist; absence from a list of examples is not authorisation. Canadian status can be checked in the Drug Product Database, and the framework is set out in peptides and Canadian law.
What is kisspeptin-10 commonly confused with?
Kisspeptin-54. Same gene, same receptor, a longer molecule, and the form used in the IVF trials.
GnRH and its analogues. GnRH acts at the pituitary, one level below kisspeptin. GnRH analogues such as triptorelin are approved medicines; no kisspeptin is.
A testosterone product. Kisspeptin-10 contains no hormone and acts only through an intact axis. The 2026 data show the gonadotropin response fading under continuous exposure, which is the opposite of a steady supply.
PT-141. Both appear in discussions of sexual and reproductive signalling, but PT-141 acts at melanocortin receptors and holds a US approval for one indication; see what is PT-141.
A cancer drug. The "metastasis suppressor" origin is real, but it describes how the gene was found. Kisspeptin-10 is not an approved or established anticancer agent.
Supplied here for laboratory use: Kisspeptin-10. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
The studies above describe the peptide in the healthy volunteers enrolled. They are not evidence about any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
Why is it called kisspeptin? Because it comes from the KiSS-1 gene, named by the Pennsylvania group that isolated it in 1996 from melanoma cells. The peptides encoded by that gene were named kisspeptins in 2001 by Kotani and colleagues; the Takeda group independently called the 54-residue form metastin, after the gene's link to suppressing metastasis.
What is the difference between kisspeptin-10 and kisspeptin-54? Kisspeptin-54 is the long form; kisspeptin-10 is its last ten residues, which carry the receptor-activating sequence. Both act at KISS1R. In healthy men they produced similar gonadotropin rises in a direct comparison. The long form, not kisspeptin-10, was the one used in the IVF oocyte-maturation trials.
Does kisspeptin-10 work the same in women and men? No. Healthy men responded at low levels, while women in the follicular phase of the menstrual cycle showed no gonadotropin change even at the highest levels tested. Women in the preovulatory phase did respond. Any result in one sex should not be assumed to carry over to the other.
Has kisspeptin-10 been tested as a treatment? Not in any published therapeutic trial that we found. The human studies are physiology studies in healthy volunteers that measure LH, FSH and sex steroids. Treatment-oriented work has used kisspeptin-54 or engineered agonists such as MVT-602, and none has led to an approval.
Selected Research References
- Lee JH, Miele ME, Hicks DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. Journal of the National Cancer Institute. 1996;88(23):1731-1737. pubmed.ncbi.nlm.nih.gov/8944003
- Ohtaki T, Shintani Y, Honda S, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411(6837):613-617. pubmed.ncbi.nlm.nih.gov/11385580
- Kotani M, Detheux M, Vandenbogaerde A, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. Journal of Biological Chemistry. 2001;276(37):34631-34636. pubmed.ncbi.nlm.nih.gov/11457843
- de Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences of the USA. 2003;100(19):10972-10976. pubmed.ncbi.nlm.nih.gov/12944565
- Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. New England Journal of Medicine. 2003;349(17):1614-1627. pubmed.ncbi.nlm.nih.gov/14573733
- George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. Journal of Clinical Endocrinology & Metabolism. 2011;96(8):E1228-E1236. pubmed.ncbi.nlm.nih.gov/21632807
- Jayasena CN, Nijher GM, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. Journal of Clinical Endocrinology & Metabolism. 2011;96(12):E1963-E1972. pubmed.ncbi.nlm.nih.gov/21976724
- Jayasena CN, Abbara A, Narayanaswamy S, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human Reproduction. 2015;30(8):1934-1941. pubmed.ncbi.nlm.nih.gov/26089302
- Yeung AC, Phylactou M, Koysombat K, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. European Journal of Endocrinology. 2026;195(2):206-216. pubmed.ncbi.nlm.nih.gov/42549827
- Abbara A, Ufer M, Voors-Pette C, et al. Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals. Fertility and Sterility. 2024;121(1):95-106. pubmed.ncbi.nlm.nih.gov/37925096
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
